Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
June 12 2014 - 9:00AM
Marketwired
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider
Range of Cancers
NEW YORK, NY--(Marketwired - Jun 12, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) and its shareholders should soon experience an event
that, to date, has not been enjoyed by the Maryland biotech
firm. With preclinical studies set to begin any day now at
Translational Drug Development (TD2), this is the first time the
pancreatic cancer treatment that combines the live-cell
encapsulation technology Cell-in-a-Box® with the anticancer drug
ifosfamide will enter the clinic under the Nuvilex name.
These studies will have the company entering the clinic in an
effort to treat symptoms related to pancreatic cancer, but could
have it leaving the clinic with the potential to treat a host of
abdominal cancers that include; liver cancer, stomach cancer,
colorectal cancer, and kidney cancer among others.
Abdominal cancer is a general term for a variety of cancers, and
it is a type of cancer that occurs when there is an uncontrolled
growth of abnormal cells anywhere in the abdomen, the area between
the lower chest and the groin. The abdomen consists of many organs,
including the stomach, intestines, liver, gallbladder, pancreas,
esophagus, and numerous blood vessels.
If the preclinical trials produce the results expected and can
relieve the unbearable pain and slow the onset of ascites
associated with advanced pancreatic cancer as well as other
abdominal cancers, Nuvilex and its Cell-in-a-Box®/ifosfamide
combination could find itself heading to Phase I-II clinical trials
quickly with the potential of being added as part of a treatment
regimen for a variety of abdominal cancers to relieve symptoms for
close to a million new cancer cases every year.
The American Cancer Society estimates that in 2014 around 46,000
people will be diagnosed with pancreatic cancer in the US, but
Nuvilex could find itself with a treatment that could help many
more patients with the symptoms associated with other abdominal
cancers.
Liver cancer, for instance, will be diagnosed in more than
700,000 new patients each year around the world. Liver cancer
is a leading cause of cancer deaths worldwide, accounting for more
than 600,000 deaths each year.
Meanwhile, the American Cancer Society estimates that 136,830
people will be diagnosed with colorectal cancer this year in the US
alone, and 50,310 people in the country will die from the disease
in 2014.
So, the work by TD2 in the clinic could very well prove that
Nuvilex is headed for much bigger opportunities to treat deadly
cancers. And, while this will be good news for shareholders,
it's the best news for those patients looking for relief of the
symptoms that are often seen as the reason many with these
abdominal cancers give up.
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex content by a third party who reserves the
right to buy, sell or remain neutral on securities after the
publication of this article. SMMG has received total compensation
of $97,685 for all created content related to Nuvilex.
Additionally, a principal at SMMG currently owns 200,000 total
shares of Nuvilex issued by the company through a consulting
agreement which has since ended for work unrelated to content
development. All shares have been held for the requisite period
under Rule 144 as of April 30, 2014, and are eligible to be sold
immediately without further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact